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IGNACIO MELERO, CHENG QIAN, AND JESU´S PRIETO
The use of gene therapy to enhance antitumor immunity
has emerged as a promising procedure to fight cancer. In this
study we have tested the ability of an adenovirus carrying
interleukin 12 (IL-12) gene (AdCMVIL-12) to eliminate tu-
moral lesions in 3 animal models of orthotopic hepatocellu-
lar carcinoma (HCC). Intratumoral injection of AdCM-
VIL-12 in animals with a single big tumor nodule implanted
in the liver resulted in significant inhibition of tumor growth
in a dose-dependent manner. Fifty percent of animals that
received a dose of 5 3 109 plaque-forming units, showed
complete regression of the tumor 2 weeks after treatment. In
animals with 2 independent tumor nodules in the left
liver lobe, injection in only one of them of 5 3 109 pfu
AdCMVIL-12 induced, 15 days after therapy, complete re-
gression of 50% of treated tumors and also of 50% of un-
treated lesions, with 60% long-term survival. Rats that were
tumor free after therapy with AdCMVIL-12 showed protec-
tion against tumor rechallenge. A group of rats received the
carcinogen diethylnitrosamine and developed multiple he-
patic dysplasic nodules of 1 to 5 mm in diameter. These
animals were treated by intrahepatic artery injection of ei-
ther AdCMVIL-12 (5 3 109 pfu) or control vector. In this
model AdCMVIL-12 induced complete tumor regression in
20% of treated rats and inhibited tumor growth in 60% of
cases with an increase in rat survival. Activation of natural
killer (NK) cells and inhibition of angiogenesis were found
to be antitumor mechanisms set in motion by AdCMVIL-12.
Our data indicate that experimental HCC can be efficiently
treated by intratumoral or intravascular injection of adeno-
virus expressing IL-12. (HEPATOLOGY 2001;33:52-61.)
Hepatocellular carcinoma (HCC) is a common human ma-
lignancy that resists conventional chemotherapy and radio-
therapy.1-3 Current treatment of small, apparently solitary,
nodules is based on partial hepatectomy or transplantation,3,4
but there is no efficient treatment of patients with multiple
tumor nodules.1-3
The use of gene therapy with immunostimulatory cyto-
kines to enhance immunologic responses against tumor cells
has emerged as a promising new approach to treat cancer.5,6
This form of therapy can be accomplished either by ex vivo
transduction of tumor cells or fibroblasts or by direct in vivo
transduction of the tumor and adjacent tissue with cytokine
genes such as interleukin 2 (IL-2), IL-4, IL-6, IL-7, IL-12,
interferon gamma (INF-g), tumor necrosis factor, and granu-
locyte macrophage–colony-stimulating factor.5,6
IL-12 (also named natural killer cell [NK] stimulatory fac-
tor) was originally identified as a factor secreted by Epstein-
Barr virus–transformed human B cell lines that mediates sev-
eral biological activities on T lymphocytes and natural killer
(NK) cells.7 IL-12 is produced by B cells, dendritic cells, and
macrophages.8,9 It acts on T cells and NK cells to induce pro-
liferation and production of cytokines (especially IFN-g) and
to enhance generation and activity of cytotoxic lymphocytes.
IL-12 is a key factor in the induction of macrophage activation
leading to differentiation of uncommitted T lymphocytes to
Th1 cells.8,9 Systemic treatment with purified recombinant
IL-12 has been shown to induce antitumor effects in different
animal models.10-14 The mechanisms of anti-tumoral activity
of IL-12 include the activation of tumor-specific cytotoxic T
lymphocytes (CTL) and NK cells and also the ability of this
cytokine to inhibit angiogenesis in vivo.10,14-17 The anti-angio-
genic effect of IL-12 is mediated by IFN-g, which in turn
stimulates the production of the chemokine IFN-inducible
protein-1016,17 that, in addition to acting as a chemoattractant
for lymphocytes, has a powerful inhibitory effect on prolifer-
ation and differentiation of endothelial cells.18-20 Moreover,
IL-12–stimulated NK cells are cytotoxic for activated endo-
thelium thus contributing to block the formation of new tu-
moral vessels.21
Although systemic administration of IL-12 has been shown
to be highly effective in inducing tumor regression and reduc-
ing metastases in diverse murine models of solid tumors,10-14
important hematologic, hepatotoxic and muscular side effects
limit its use as an anticancer agent.22,23 A phase I clinical trial
of systemic IL-12 treatment in subjects with renal cell carci-
noma showed objective tumor responses in several patients,
but a subsequent phase II trial of IL-12 in advanced renal cell
cancer was discontinued because of severe toxicity, including
death.24,25 It seems therefore that the use of procedures allow-
ing high local production of IL-12 at the site of interest (the
tumor mass) with low systemic levels of the cytokine would
achieve similar or better therapeutic effects with less toxicity.
To this aim different strategies based on the transduction of
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tumoral cells with IL-12 genes have been attempted to treat
various experimental neoplasms.15,26-32
Although some studies have already shown that intratu-
moral injection of vectors coding for IL-12 causes tumor re-
gression in animals with subcutaneous tumors,28-32 these re-
sults cannot be directly applied to orthotopic HCC. In
contrast to orthotopic models, subcutaneous tumors display a
high inherent immunogenicity caused by the presence in this
localization of dendritic cells, which are very efficient at pre-
senting tumoral antigens and eliciting immune responses.15,33
Thus, the successful generation of antitumoral immunity
against subcutaneous tumors does not necessarily indicate the
same efficacy against tumors at an orthotopic site. Moreover,
the therapeutic effects obtained in transplanted tumors may
not apply to the case of tumors that arise in animals as a result
of carcinogenic events. Since there are no data in the literature
relating the effects of IL-12 gene transfer to orthotopic pri-
mary liver cancer, in the present study we have evaluated the
antitumoral efficacy and effector mechanisms of adenovirus-
mediated gene transfer of IL-12 in 3 models of this malig-
nancy. Experimental models for HCC were generated either
by inoculation of syngenic HCC cells into the liver of Buffalo
rats to produce 1 or 2 tumor nodules or by chronic adminis-
tration of the carcinogen diethylnitrosamine (DENA) to
Wistar rats to obtain multifocal HCC. Our data show that
treatment with adenovirus expressing IL-12 results in a
marked antitumoral effect in all HCC models analyzed. This
antitumor effect correlated with activation of NK cells and
inhibition of angiogenesis in vivo.
MATERIALS AND METHODS
Animals and Cell Lines
Five- to 8-week-old male Buffalo rats and 6-week-old Wistar rats
were obtained from Harlan (Barcelona, Spain). During the experi-
mental period animals were housed in standard conditions and all
animals received humane care according to the criteria outlined in
the “Guide for the Care and Use of Laboratory Animals” prepared by
the National Academy of Sciences.
The 293 cell line (adenoviral E1 transformed human embryonic
kidney cells), McA-RH7777 (HCC cell line from Buffalo rat), CC531
(colon cancer cell line from WAG rat), and YAC-1 (Moloney leuke-
mia virus–transformed lymphoma cell line derived from A/Sn mice)
were purchased from American Type Culture Collection (Rockville,
MD). The 293 and CC531 cell lines were cultured in Dulbecco’s
modified Eagle medium supplemented with 10% heat-inactivated
fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin. McA-RH7777 cells were cultured in Dul-
becco’s modified Eagle medium supplemented with 20% heat-inac-
tivated horse serum and 5% heat-inactivated fetal bovine serum.
YAC-1 cells were cultured in RPMI 1640 medium with 10% heat-
inactivated fetal bovine serum.
Construction of Recombinant Adenoviral Vectors
Adenovirus carrying LacZ reporter gene (AdCMVlacZ) and IL-12
(AdCMVIL-12) under the control of CMV promoter were produced
as reported previously.34,35 Recombinant adenoviruses were isolated
from a single plaque, expended in 293 cells, and purified by double
cesium chloride ultracentrifugation. Purified virus was extensively
dialyzed against 10 mmol/L Tris/1 mmol/L MgCl2 and stored in ali-
quots at 280°C. Titration was made by plaque assay.
Induction of Orthotopic HCC and In Vivo Gene Therapy
Three experimental models have been developed for this study:
Model 1 (Single HCC Nodule). A total of 106 of McA-RH7777 cells
were inoculated into the left liver lobe of Buffalo rats. A single tumor
nodule (10-12 mm in diameter) was observed 2 weeks after inocula-
tion of tumor cells. These animals were treated either with AdCM-
VIL-12 at different doses (5 3 109, 109, 108, 107 plaque-forming
units/animal) or AdCMVlacZ (5 3 109 pfu/animal) as a control.
Vectors were given by intratumoral injection. Two weeks after treat-
ment, animals were sacrificed and liver samples were obtained for
evaluation of treatment efficacy. Spleen was obtained for cytotoxicity
assays.
Model 2 (Two Independent HCC Nodules). Two tumors were im-
planted in the liver by intrahepatic inoculation of 5 3 105 of McA-
RH7777 cells into the left liver lobe of Buffalo rats. Two tumor nod-
ules of 8 to 10 mm in diameter developed 10 days after inoculation of
tumor cells. One tumor nodule was treated either with AdCMVIL-12
at 5 3 109 pfu/animal or control vector AdCMVlacZ at same dose.
Vectors were given by intratumoral injection. Two weeks after treat-
ment, animals were anesthetized and underwent laparotomy to ob-
serve the evolution of the tumor. Survival was checked daily in all of
the animals.
Model 3 (Multiple HCC Nodules). Primary liver tumors were induced
in Wistar rats (6 weeks old, 170 g) with DENA (Sigma, St. Louis,
MO) as described previously.36 Briefly, animals received 10 mg/kg/d
of DENA for 12 weeks. The weight of the rats was recorded every
week. Rats were given weekly doses of DENA in a volume corre-
sponding to the estimated water consumption of 6 days of drinking
water (0.01% vol/vol). Once the animals consumed the administered
DENA solution, they were given DENA-free water the rest of the
week. DENA solution was prepared each week. Tumor formation
was monitored by weekly sacrifice of 1 rat during the period of DENA
administration. At the end of the induction period, rats presented
multiple tumor nodules in the liver ranging from microscopic neo-
plastic nodules to HCC nodules with diameter up to 5 mm. Twenty-
four tumor-bearing rats were divided randomly into 3 groups: the
treated group received 5 3 109 pfu of AdCMVIL-12 (n 5 10) and
control groups received either 5 3 109 pfu of control vector AdCM-
VlacZ (n 5 6) or saline (n 5 8). Vectors were given by infusion via
hepatic artery. To this aim, rats were anesthetized with ketamine-
atropine-diazepam and a butterfly with a 27-gauge needle was in-
serted into the gastroduodenal artery using an operating microscope
(magnification 316). After administration of AdCMVIL-12 or saline,
the gastroduodenal artery was ligated and the presence of appropri-
ate hepatic blood flow was confirmed. Two weeks after treatment,
treated animals were anesthetized and laparotomized to observe the
evolution of the tumor. Tumor burden was evaluated before and 2
weeks after treatment by 2 independent observers according to the
score system described in Table 1. One month after treatment, 5 of 10
rats from the AdCMVIL-12–treated group and 2 of 6 rats from the
AdCMVlacZ–treated group and 2 of 8 rats from the control group
receiving saline were sacrificed. The evolution of the tumor was
assessed as indicated above. Survival was checked daily in the re-
maining animals.
Cytokine Production
Tumor-bearing animals were treated by intratumor injection of
5 3 109 pfu/animal or control vector AdCMVlacZ at the same dose of
TABLE 1. Evaluation of Tumor Burden in Primary Liver Cancer
Induced by DENA
Tumor Score
No. of Tumor
Nodules
Size of Tumor
Nodules Metastasis
0 0 0 No
1 1-3 ,2 mm No
2 1-3 2-5 mm No
3 3-5 2-5 mm No
4 .5 2-5 mm No
5 .5 .5 mm No
6 .5 .5 mm Yes
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saline. Blood samples were collected from the retro-orbital sinus at 1,
3, 5, and 7 days after treatment. Serum mouse IL-12 (the transgen
contained in AdCMVIL-12) and rat IFN-g (the main cytokine in-
duced by IL-12) were determined by enzyme-linked immunosorbent
assay with commercial kits (Biosource, Nivelles, Belgium) following
the manufacturer’s instructions.
Cytotoxicity Assay
Cytotoxicity assay was performed according to standard protocols
as described before.37,38 Viable splenocytes were tested for CTL ac-
tivity after incubation for 5 days of 6 3 106 cells together with 2.5 3
105 McA-RH7777 cells (previously treated with 100 mg/mL of mit-
omycin C for 30 minutes at 37°C) in each well of a 24-well plate. On
day 5, fresh tumor cells were harvested and 1 3 106 cells were labeled
with 50 mCi 51Cr for 1 hour. After labeling, the cells were washed 4
times, adjusted to 5 3 104/mL, and 100 mL of this cell suspension was
added to a 96-well plate and incubated with effector cells for 5 hours
at 37°C in different E/T cell ratios. To determine NK activity, spleno-
cytes were obtained as effector cells and 3 types of target cells (McA-
RH7777, YAC-1, and CC531) were used. In some experiments in
vitro blockade of CD41, CD81, and major histocompatibility com-
plex (MHC) class I1 cells was performed by using purified anti-rat
CD4 (clone OX-35, Pharmingen, San Diego, CA), anti-rat CD8a
(clone OX-8 Pharmingen), and anti-rat RT1A (clone OX-18 Pharmi-
gen) at final concentration of 100 mg/mL. Spontaneous and maxi-
mum release of 51Cr from tumor cells were determined, the latter
using 0.8% Triton X-100. After incubation, radioactivity was mea-
sured in 50-mL aliquots of the supernatants. Data represent the
means of triplicate cultures. The percent of specific lysis was calcu-
lated using the formula (c.p.m. experimental sample 2 c.p.m. back-
ground)/(c.p.m. maximum lysis 2 c.p.m. background) 3 100.
Assay for Antiangiogenic Activity of the Transgene
Fifty microliters of Matrigel (Becton-Dickinson, Bedford, MA)
mixed with VEGF165 (Peprotech, London, England) at final concen-
tration of 20 ng/mL was injected into the middle lobe of livers of
tumor-bearing animals. At same time, a single tumor nodule (8-10
mm in diameter) previously implanted in the left liver lobe was
treated using 5 3 109 pfu of either AdCMVIL-12 or control vector
AdCMVlacZ. After 10 days, rats were sacrificed and the middle lobe
of livers that contained the Matrigel plug was removed, fixed in 10%
buffered formalin and embedded in paraffin. The samples were sec-
tioned and stained with hematoxylin-eosin for histologic analysis.
The number of vascular cells was determined using a computerized
digital analyzer Optimas 6.2 (Optimas Corporation, Bothell, Washing-
ton). The results are expressed as the mean number of cells in 105 mm2.
FIG. 1. In vivo gene therapy of established HCC cancer. Rats with ortho-
topic HCC tumor nodule (10-12 mm in diameter) were treated either with
AdCMVIL-12 at different doses (5 3 109 pfu [n 5 8], 109 pfu [n 5 8], 108 pfu
[n 5 3], 107 pfu [n 5 3]), or control adenovirus AdCMVlacZ at 5 3 109 pfu
(n 5 9), or saline (n 5 6). Two weeks after treatment, the animals were
sacrificed and liver samples were obtained for evaluation of tumors. Size of
tumor was measured before and 2 weeks after treatment. *P , .01 as com-
pared with control animals.
FIG. 2. Macroscopic aspect of the liver in rats before and 2 weeks after
treatment with AdCMVIL-12 or AdCMVlacZ. (A) Liver from an animal before
treatment showing a single tumor nodule of about 10 mm in diameter. (B)
Liver from a control rat treated with AdCMVlacZ showing the presence of a
large tumor of about 20 mm in diameter. (C) Liver from a rat treated with
AdCMVIL-12 showing absence of tumor.
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RESULTS
In Vivo Gene Therapy of Orthotopic HCC Tumor Nodule With
AdCMVIL-12
In a model of colon cancer we have previously shown that
intratumoral injection of AdCMVIL-12 resulted in the pro-
duction of high levels of IL-12 within the tumor mass and
subsequent tumor regression.35 To investigate whether AdC-
MVIL-12 could have therapeutic effects in immunocompetent
animal models of HCC, we produced a tumor nodule in the
liver by implantation of the syngeneic hepatocarcinoma cell
line McA-RH7777 into the left liver lobe of Buffalo rats. When
tumor size was 10 to 12 mm in diameter, animals were treated
by intratumoral injection of AdCMVIL-12 at different doses
(5 3 109, 109, 108, 107 pfu), control adenovirus AdCMVlacZ
at 5 3 109 pfu or saline. Two weeks after treatment, animals
were sacrificed and liver samples were obtained for evaluation
of the therapy. Figure 1 shows that in all animals treated with
saline or AdCMVlacZ the size of the tumors increased pro-
gressively. In contrast, inhibition of tumor growth was ob-
served in animals treated with AdCMVIL-12 in a dose-depen-
dent manner. Even the lowest dose of AdCMVIL-12 (107 pfu)
reduced tumor growth. Four of 8 animals treated with high
dose of AdCMVIL-12 (5 3 109 pfu) and 3 of 8 animals treated
with intermediate dose of AdCMVIL-12 (109 pfu) exhibited a
complete regression of the tumor (Fig. 1). Figure 2 shows
representative photographs of livers with implanted HCC tu-
mors before and 2 weeks after therapy with either AdCM-
VIL-12 or control vector. In rats in which the tumor was
treated with control vector a lesion of more than 20 mm in
diameter was present 15 days after therapy whereas no tumor
or very small tumor nodules were found in AdCMVIL-12–
treated rats. These data show a marked antitumoral effect of
AdCMVIL-12 in this animal model of liver cancer.
Local AdCMVIL-12 Gene Therapy of HCC Induces Not Only Local
But Also Distant Antitumoral Effects
Because in most cases of patients with HCC there are mul-
tiple tumor nodules in the liver, we evaluated whether injec-
tion of AdCMVIL-12 into a tumor nodule had any effect on
distant lesions. To this aim we used the Buffalo rat HCC model
with 2 tumor nodules in the liver. When tumors were 8 to 10
mm in diameter, one of the nodules was treated with 5 3 109
pfu of AdCMVIL-12 or AdCMVlacZ as control. We observed
that all animals from the control group experienced a progres-
sive tumor growth and died by day 40 (Fig. 3). In contrast,
treatment with AdCMVIL-12 induced complete tumor disap-
pearance of the treated lesion in 5 of 10 animals 2 weeks after
therapy (Fig. 3A) and also a complete regression of the un-
treated tumor in 5 of 10 rats (Fig. 3B). The rest of animals that
received AdCMVIL-12 had partial tumor regression. We also
found that treatment with AdCMVIL-12 increased survival of
tumor-bearing animals for more than 1 year as shown in Fig.
3C. These data indicate that, in our model, adenoviral gene
transfer of IL-12 to a tumor nodule can exert a therapeutic
effect not only on the treated lesion but also on distant nod-
ules within the liver.
Long-Term Antitumor Immunity Induced by Intratumoral Injection
of AdCMVIL-12
To know whether local treatment of HCC with AdCM-
VIL-12 could induce lasting immunologic memory, we re-
challenged animals that were free of tumor after AdCMVIL-12
FIG. 3. Local injection of AdCMVIL-12 into one tumor induces distant
antitumoral effect in animals with two orthotopic HCC tumor nodules. When
tumors reached 8 to 10 mm in diameter 1 of the 2 tumor nodules was treated
by intratumoral administration of 5 3 109 pfu of AdCMVIL-12 (n 5 10) or
control vector AdCMVlacZ (n 5 10). The size of the tumors was measured
before and 2 weeks after treatment and survival of animals was recorded. (A)
Size of treated tumors in animals that received intratumoral injection of
AdCMVIL-12 or control adenovirus AdCMVlacZ. (B) Size of untreated tu-
mors in animals in which the distant tumor was treated with AdCMVIL-12 or
control adenovirus AdCMVlacZ. (C) Long-term survival of animals after
treatment with AdCMVIL-12 and AdCMVlacZ. *P , .01 as compared with
control animals.
FIG. 4. Long-term protection against parental HCC cell rechallenge.
McA-RH7777 cells (1 3 106 cells) were inoculated subcutaneously into the
flank of animals that had completely eliminated the intrahepatic tumors after
therapy with AdCMVIL-12 (n 5 10). The same amount of McA-RH7777 cells
were injected into the flank of age- and sex-matched naive animals (n 5 6).
The occurrence of subcutaneous tumor growth was documented and results
were expressed as percentage of animals free of tumor.
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treatment with a new subcutaneous administration of McA-
RH7777 cells 3 months after complete regression of primary
tumors. Figure 4 shows that all animals (10 of 10) which had
eliminated the tumor after AdCMVIL-12 therapy were resis-
tant to new challenge with a subcutaneous injection of 106
parental McA-RH7777 cells, whereas all naive rats showed
tumor growth at the site of injection 7 to 8 days after inocu-
lation of cancer cells. These data indicate that in vivo gene
therapy using AdCMVIL-12 vector may induce long-term
protection against tumor recurrence.
In Vivo Gene Therapy With AdCMVIL-12 of Multifocal HCC
Induced by DENA in Rats
The carcinogen DENA induces multiple tumor nodules in
the liver through different steps of initiation, promotion, and
tumor progression.39-41 DENA-induced HCC is a very difficult
FIG. 5. In vivo gene therapy of established multifocal HCC induced by
DENA. Rats with multiple dysplastic nodules of 1 to 5 mm in diameter in liver
induced by the carcinogen diethylnitrosamine were treated by intrahepatic
arterial infusion of either AdCMVIL-12 (5 3 109 pfu, n 5 10), or control
vector AdCMVlacZ (n 5 6), or saline (n 5 8). Tumor burden (score as
described in the Materials and Methods and Table 1) was measured just
before and 2 weeks after treatment. Four rats from the control group and 5
rats that received AdCMVIL-12 therapy were sacrificed 1 month after treat-
ment. Liver samples were obtained for evaluation of tumors and blood sam-
ples were collected for biochemical analysis. The rest of the animals were left
for assessment of survival. (A) Tumor score in animals with DENA-induced
HCC before and after gene therapy with AdCMVIL-12 or control treatment.
Tumor score was expressed as mean and standard error. *P , .01 as com-
pared with control animals. ( ), Saline; ( ), AdCMVlacZ; (n ), AdCMVIL-
12. (B) Survival of rats with DENA-induced HCC after gene therapy with
AdCMVIL-12 or control treatment. (), Saline; (F), AdCMVlacZ; (n ), AdC-
MVIL-12.
FIG. 6. Biochemical data in animals with DENA-induced HCC that re-
ceived AdCMVIL-12 or control treatment (AdCMVlacZ or saline). Data are
presented as mean and standard error. *P , .01 as compared with controls.
ALT, alanine transaminase.
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neoplasm to treat. This animal model of aggressive multifocal
liver cancer is a hard test to evaluate the capabilities of gene
therapy in liver cancer.36,42,43 We therefore administered in-
tra-arterially AdCMVIL-12 (5 3 109 pfu, n 5 10), AdCMV-
lacZ (5 3 109 pfu, n 5 6), or saline (n 5 8) to rats with
DENA-induced HCC. Tumor burden, expressed as tumor
score (see Materials and Methods and Table 1), was assessed
before treatment and 2 weeks later. Four rats from control
groups and 5 rats that received AdCMVIL-12 therapy were
sacrificed 1 month after treatment; livers were evaluated for
tumor burden and blood samples were collected for biochem-
ical analysis. The rest of the animals were followed up for
survival. Figure 5A shows that tumor score increased in all
animals from control groups during the 2 weeks that followed
treatment. In contrast, among the 10 rats that received
AdCMVIL-12 2 animals experienced complete tumor regres-
sion, in 6 rats tumor score remained stable, and in only 2
animals we observed an increase of tumor score. At the time of
sacrifice of a representative sample of animals (4 weeks after
treatment) 1 of 5 animals treated with AdCMVIL-12 was free
of tumor, 1 rat showed tumor progression, and in 3 rats tumor
score was stabilized. In contrast, tumor progression was ob-
served in all control rats. According to these observations,
treatment with AdCMVIL-12 resulted in a substantial increase
of survival as shown in Fig. 5B. Although all control animals
had died before day 96, survival of AdCMVIL-12–treated rats
at this time point was 60%. All AdCMVIL-12–treated animals,
however, died by day 130.
To evaluate biochemical changes 1 month after therapy we
considered together the 2 control groups because they were
comparable with respect to tumor burden and survival. As
shown in Fig. 6 treatment with AdCMVIL-12 was associated
with a decrease in serum level of alanine transaminase and
bilirubin and an increase of glycemia as compared with con-
trols, indicating AdCMVIL-12 therapy was not associated
with hepatotoxicity but rather with improved liver biochem-
istry in animals with widespread liver cancer.
Production of Cytokines Following Intratumoral Injection of
AdCMVIL-12
To examine if AdCMVIL-12 treatment induced production
of cytokines in our model, a time course of expression of IL-12
and IFN-g after intratumoral injection of 5 3 109 pfu of either
AdCMVIL-12 or AdCMVlacZ or saline was performed along a
period of 7 days. We found that tumor-bearing rats treated
with AdCMVIL-12 produced IL-12 with maximal values at
day 1 after the administration of AdCMVIL-12. Expression of
IL-12 lasted for 3 days, because circulating levels of IL-12
could not be detected on day 5 and 7 (Table 2). In animals
receiving control vector AdCMVlacZ or saline, serum IL-12
was undetectable (Table 2). Since IL-12 is a strong inducer of
IFN-g,8,14 we also measured the production of IFN-g in sera
from treated animals. As shown in Table 2, animals receiving
AdCMVIL-12 produced high serum level of IFN-g at all time
points. INF-g was not detectable in sera from animals receiv-
ing control vector AdCMVlacZ or saline.
AdCMVIL-12 Elicits Antitumoral NK Cell Response
We have explored whether the antitumor effects induced
by AdCMVIL-12 were mediated by activation of NK and/or
cytotoxic T lymphocytes. To this aim mononuclear cells were
isolated from spleens of tumor-bearing rats at days 1, 3, 5, and
8 after administration of either AdCMVIL-12 or control vector
AdCMVlacZ. In assays to analyze specific antitumor CTL ac-
tivity we could not detect significant cytotoxicity against
McA-RH7777 cells in tumor-bearing animals treated with ei-
ther AdCMVIL-12 or AdCMVlacZ. To ascertain that the lack
of specific CTL activity was not caused by any possible immu-
nosuppressive effect of high doses of AdCMVIL-12,44 we per-
formed the CTL assays in tumor-bearing animals receiving
lower doses of AdCMVIL-12 (109, 108, and 107 pfu). Still, no
CTL responses against McA-RH7777 cells were found (data
not shown).
As mentioned in the Materials and Methods, NK cell activ-
ity was measured using YAC-1 (NK-sensitive cells), McA-
RH7777 (parental tumor cells), and CC531 (unrelated colon
cancer) as target cells. As shown in Fig. 7A and 7B significant
cytotoxic NK activity against McA-RH7777 and YAC-1 cells
was elicited by intratumoral administration of AdCMVIL-12.
NK cytotoxicity was highest at day 3 after therapy and de-
clined rapidly on subsequent days. Some cytotoxicity was also
detected when using unrelated colon cancer cells (CC531) as
targets although this effect was clearly less notorious than
with the other 2 cell lines (Fig. 7C). However, in animals
receiving control vector AdCMVlacZ only a modest elevation
in NK activity was observed. Addition of antibodies against
CD4 or CD8 did not inhibit the cytotoxic effect on McA-
RH7777 cells and antibody against MHC class I only slightly
decreased cytotoxicity against these target cells (Fig. 8). Our
data indicate that in our animal model of HCC AdCMVIL-12
strongly stimulates NK activity against tumoral cells.
AdCMVIL-12 Elicits Antiangiogenic Effects
To know whether nonimmunologic mechanisms, particu-
larly antiangiogenesis, were involved in the regression of HCC
induced by AdCMVIL-12 we analyzed the vascularization that
TABLE 2. Production of IL-12 and IFN-g in Sera Following Treatment With AdCMVIL-12
Day 1 Day 3 Day 5 Day 7
IL-12
AdCMVIL-12 2026.73 6 933.86 123.48 6 97.41 ud ud
AdCMVlacZ ud ud ud ud
Saline ud ud ud ud
IFN-g
AdCMVIL-12 1234.19 6 298.07 778.58 6 163.45 413.29 6 74.53 938.12 6 364.31
AdCMVlacZ ud ud ud ud
Saline ud ud ud ud
NOTE. Tumor-bearing rats were treated by intratumoral injection of 5 3 109 pfu of either AdCMVIL-12 (n 5 4) or AdCMVlacZ (n 5 4) or saline (n 5 2).
Sera were collected on days 1, 3, 5, and 7 after treatment.
Abbreviation: ud, undetectable.
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develops in a Matrigel plug embedded in VEGF and placed
into the liver. Animals with a tumor of 8 to 10 mm in diameter
implanted in the liver were inoculated with VEGF-containing
Matrigel into the same lobe and received at the same time an
intratumor injection of 5 3 109 pfu of either AdCMVIL-12 or
AdCMVlacZ. Ten days after treatment, the Matrigel plugs and
surrounding liver tissue were obtained for histologic exami-
nation. As shown in Fig. 9A an intense invasion by endothe-
lium-like cells was observed in Matrigel plugs from AdCMV-
lacZ-treated rats. In contrast, Matrigel plugs from rats that
received AdCMVIL-12 were almost completely free of endo-
thelium-like cells (Fig. 9B). Angiogenesis was quantitated in
all plugs by measuring the number of endothelium-like cells
on Matrigel sections using a computerized automatic ana-
lyzer. Figure 9C shows that AdCMVIL-12 treatment resulted
in inhibition of VEGF-induced angiogenesis by 70%, as com-
pared with cases treated with AdCMVlacZ.
DISCUSSION
IL-12 is a strong activator of cellular immunity, which has
been shown to possess powerful antitumoral activities.8-10
However, the use of recombinant IL-12 as an antitumoral
agent is hampered by the toxicity of this cytokine when used
at therapeutic doses.22-25 This toxicity is mainly due to the
ability of IL-12 to induce INF-g production.22,23 In contrast to
the systemic administration of the recombinant protein, it
seems possible that procedures allowing local synthesis of
IL-12 may result in antitumoral effects without accompanying
toxicity. This can be achieved by IL-12 gene delivery to the
tumoral lesion or its surroundings. In this study we selected
an adenoviral vector to transfer IL-12 to orthotopic HCC be-
cause of the ability of adenovirus to efficiently transduce
hepatocytes and HCC cells.34,36,45-48 Adenoviral vectors do
not integrate into the host genome and the expression of the
transgenes is transient lasting only 7 to 10 days.49 This short
period could nevertheless be sufficient for treatment of can-
FIG. 8. Effect of anti-CD4, anti-CD8, and anti-MHC class I antibodies on
NK activity. Splenocytes were isolated at days 3 from animals treated with
AdCMVIL-12 (as in Fig. 7) and assayed against 51Cr-labeled parental tumor
McA-RH7777 cells in the presence of purified anti-rat CD4, anti-rat CD8a,
and anti-rat RT1A at final concentration of 100 mg/mL, respectively. (n ),
Control; ( ), anti-CD8; ( ), anti-CD4; (h), anti-MHC I.
FIG. 7. NK activity in rats with HCC implanted in the liver that received
intratumoral injections of either AdCMVIL-12, AdCMVlacZ, or saline.
Splenocytes were isolated 1, 3, 5, and 8 days after therapy and assayed against
51Cr-labeled parental tumor cells McA-RH7777 (A), NK-sensitive YAC-1 cells
(B), and unrelated colon cancer CC 531 cells (C) at different effector to target
cell ratios. Representative results of 2 independent experiments are shown.
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cer, because after stimulation of an antitumor response with
immunostimulatory cytokines the expression of the transgene
may no longer be needed.
Our data show that intratumor injection of AdCMVIL-12
resulted in complete tumor elimination in 50% of rats with 1
big tumor (10-12 mm in diameter). In the model with 2 dif-
ferent HCCs implanted in the liver we found that AdCM-
VIL-12 therapy of only 1 tumor caused regression of the
treated lesion but also of the untreated tumor nodule. Impor-
tantly this effect was accompanied by prolonged survival. Fur-
thermore those rats that completely eliminated the tumor
were resistant to new challenge with cancer cells given 3
months after complete regression of primary tumors, indicat-
ing the development of an efficient protective immunity
against parental cell line. The antitumoral effect of AdCM-
VIL-12 is apparent not only on the treated neoplasm but also
on other untreated tumors within the liver. These distant ef-
fects of locally administered AdCMVIL-12 may be a result of
the ability of this vector to induce activation of immune re-
sponses and production of cytokines that can circulate from
treated tumors to other intrahepatic neoplastic nodules. In
our study the administration of AdCMVIL-12 resulted in a
short-lived peak of serum IL-12 with highest values at day 1
and decline to undetectable level at day 5. However the pro-
duction of IFN-g was maintained at high levels at all the time
points analyzed indicating a persisting activation of the im-
mune system induced by IL-12. It is also worth noting that,
due to the strong hepatotropism of adenoviruses, intratu-
moral injection of the vector results in transduction of the
injected nodule but a proportion of the dose can escape to the
general circulation infecting hepatocytes surrounding other
liver tumors.37 Thus IL-12 could be produced not only within
the treated neoplasm but also around distant intrahepatic tu-
mor nodules, making this therapeutic approach very attrac-
tive to treat patients with multinodular liver cancer.
Because transplanted tumors, even at an orthotopic site,
might differ substantially from tumors that develop as a result
of the occurrence of carcinogenic events, we have investigated
the efficacy of AdCMVIL-12 therapy given via hepatic artery
in DENA-induced liver cancer in rats. This is a model of multi-
focal HCC, which is extremely aggressive and difficult to treat.
Recombinant IL-12 had already been shown to be able to dis-
play antitumoral effects in other models of carcinogen-induced
tumors.12,50 In previous studies we have used an adenovirus ex-
pressing the suicide gene thymidin-kinase (AdCMVtk) given by
intraportal route to treat DENA-induced liver cancer.36 Although
this therapy had a potent antitumoral effect in this model it also
caused a very high mortality among treated rats. In the present
study AdCMVIL-12 induced 20% total tumor regression and sig-
nificantly increased animal survival, although all animals died
within 130 days. Thus, the results of this therapy are considerably
better than those obtained with AdCMVtk and they open promis-
ing avenues to treat widespread HCC. The fact that despite early
effects on tumor growth no long-term survival was achieved might
be caused by the continuous generation of new neoplastic
cells from preneoplastic lesions induced by DENA whereas
the expression of IL-12 genes carried by first generation ade-
novirus was transient. Systemic administration of adenovirus
can be successfully applied only once because of the develop-
ment of neutralizing antibodies.49 It seems possible that the
development of transductionally efficient vectors, which
could be administered repeatedly or the use of vectors allow-
ing long-term (and drug-regulated) expression of the trans-
FIG. 9. Effect of AdCMVIL-12 therapy on VEGF-induced neovasculariza-
tion of Matrigel plug implanted into the liver in animals with orthotopic
HCC. A hepatic tumor (8-10 mm in diameter) was established in one lobe of
liver. Animals were treated by intratumor injection of 5 3 109 pfu of either
AdCMVIL-12 (n 5 3) or AdCMVlacZ (n 5 3) and Matrigel embedded with
VEGF was injected into another lobe of liver at the same time. Ten days later,
the Matrigel plugs and surrounding liver tissue were obtained for histologic
examination. (A) Representative photomicrograph showing VEGF-induced
neovascularization in Matrigel from animals that received control vector Ad-
CMVlacZ. (B) Representative photomicrograph showing inhibition of VEGF-
induced neovascularization in Matrigel from animals treated with AdCMVIL-
12. (C) Quantitative analysis of angiogenesis was made by counting the
number of endothelium-like cells in an area of 105 mm2. Data are presented
expressed as mean and standard deviation of 6 fields of each Matrigel plug.
*P , .01 as compared with control animals.
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gene in the liver may improve the results of IL-12–based gene
therapy of widespread liver cancer.
Activation of CD81 cells and stimulation of CTL activity
have been shown to be involved in tumor regression induced
by IL-12 in different animal tumor models.10,35 In our system
we could not detect specific antitumoral CTL activity after
AdCMVIL-12 administration but we observed a strong stim-
ulation of NK activity against parental tumor cells (McA-
RH7777) and YAC-1 cells. It has been shown that stimulation
of NK cells by IL-12 occurs via specific surface receptors9
leading to enhanced production of IFN-g and increased cyto-
toxic NK activity against tumor cells with low MHC class I
expression,9 a feature of McA-RH7777 cells used in this study
(data not shown). Our data are in accordance with other pub-
lished work in orthotopic prostate cancer model where treat-
ment with IL-12 only induced activation of NK cells, but not
tumor-specific CTL activity.15 It is possible however that in
our study AdCMVIL-12 might have produced low levels of
specific CTL that would not be detectable in the CTL assay but
that would be able to control in vivo tumor cell rechallenge
after elimination of the primary neoplasm.
In this work we found that antiangiogenesis was one of the
mechanisms contributing to tumor regression induced by
gene transfer of IL-12 to the liver. The analysis of the vascu-
larization of Matrigel plugs embedded with VEGF and im-
planted in the liver revealed that while Matrigel from animals
treated with AdCMVLacZ exhibited abundant endothelium-
like cells, there was 70% reduction in Matrigel capillaries and
endothelium-like cells in rats that received AdCMVIL-12.
These data are in agreement with recent reports showing that
IL-12 inhibits new vessel formation in models of corneal vas-
cularization in mice.16,17 Neutralizing antibodies either to
IFN-g or IFN-inducible protein-10, a CXC chemokine in-
duced by IFN-g, substantially reduced the inhibition of an-
giogenesis induced by IL-12.17 Thus, both IL-12 and the cy-
tokine cascade activated by IL-12 may induce a diversity of
biological changes including activation of NK cells and anti-
angiogenesis leading to tumor regression. These two effects,
NK activation and antiangiogenesis, may in fact be closely
related because a recent study shows that NK cells are re-
quired mediators of angiogenesis inhibition by IL-12 suggest-
ing that cytotoxic damage of endothelial cells by NK cells is a
potential mechanism by which IL-12 can suppress neovascu-
larization.21 However, the role of nonlymphocyte effector
cells such as macrophages and neutrophils should also be
considered because these cells may display antineoplastic ef-
fects and can be activated by the cytokine cascade set into
motion by IL-12.51
In conclusion, AdCMVIL-12 is an efficient vector for treat-
ment of HCC not only in animals with transplanted ortho-
topic tumor, but also in carcinogen-induced multifocal tu-
mors at doses that do not induce obvious toxicity. Our data
point to the convenience of considering IL-12–based gene
therapy as a possible therapeutic option that should be eval-
uated in patients with widespread liver cancer.
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